Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $47.18 in the prior trading day, Supernus Pharmaceuticals Inc (NASDAQ: SUPN) closed at $47.03, down -0.32%. In other words, the price has decreased by -$0.32 from its previous closing price. On the day, 0.59 million shares were traded. SUPN stock price reached its highest trading level at $48.0 during the session, while it also had its lowest trading level at $46.86.
Ratios:
Our goal is to gain a better understanding of SUPN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.19. For the most recent quarter (mrq), Quick Ratio is recorded 2.43 and its Current Ratio is at 2.58. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On February 19, 2025, Cantor Fitzgerald Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $57 to $36.
On January 06, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $57.Cantor Fitzgerald initiated its Overweight rating on January 06, 2025, with a $57 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 23 ’25 when Khattar Jack A. sold 29,513 shares for $47.23 per share. The transaction valued at 1,393,899 led to the insider holds 1,140,883 shares of the business.
Khattar Jack A. sold 16,587 shares of SUPN for $779,921 on Sep 22 ’25. The President, CEO now owns 1,122,456 shares after completing the transaction at $47.02 per share. On Sep 23 ’25, another insider, JACK A. KHATTAR, who serves as the Director of the company, bought 29,513 shares for $46.98 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SUPN now has a Market Capitalization of 2637117184 and an Enterprise Value of 2146295296. As of this moment, Supernus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 41.10, and their Forward P/E ratio for the next fiscal year is 19.30. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.96 while its Price-to-Book (P/B) ratio in mrq is 2.48. Its current Enterprise Value per Revenue stands at 3.227 whereas that against EBITDA is 16.232.
Stock Price History:
The Beta on a monthly basis for SUPN is 0.78, which has changed by 0.5083387 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, SUPN has reached a high of $47.65, while it has fallen to a 52-week low of $29.16. The 50-Day Moving Average of the stock is 12.57%, while the 200-Day Moving Average is calculated to be 31.10%.
Shares Statistics:
The stock has traded on average 815.43K shares per day over the past 3-months and 790130 shares per day over the last 10 days, according to various share statistics. A total of 56.12M shares are outstanding, with a floating share count of 52.89M. Insiders hold about 5.66% of the company’s shares, while institutions hold 106.07% stake in the company. Shares short for SUPN as of 1757894400 were 5019809 with a Short Ratio of 6.16, compared to 1755216000 on 4700980. Therefore, it implies a Short% of Shares Outstanding of 5019809 and a Short% of Float of 12.75.
Earnings Estimates
The stock of Supernus Pharmaceuticals Inc (SUPN) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.59, with high estimates of $0.62 and low estimates of $0.56.
Analysts are recommending an EPS of between $2.31 and $2.16 for the fiscal current year, implying an average EPS of $2.22. EPS for the following year is $2.44, with 3.0 analysts recommending between $2.69 and $2.15.
Revenue Estimates
5 analysts predict $175.82M in revenue for . The current quarter. It ranges from a high estimate of $183.2M to a low estimate of $161M. As of . The current estimate, Supernus Pharmaceuticals Inc’s year-ago sales were $175.69MFor the next quarter, 5 analysts are estimating revenue of $198.52M. There is a high estimate of $208.7M for the next quarter, whereas the lowest estimate is $181.8M.
A total of 5 analysts have provided revenue estimates for SUPN’s current fiscal year. The highest revenue estimate was $697.99M, while the lowest revenue estimate was $671.4M, resulting in an average revenue estimate of $689.62M. In the same quarter a year ago, actual revenue was $661.82MBased on 5 analysts’ estimates, the company’s revenue will be $814.79M in the next fiscal year. The high estimate is $843.84M and the low estimate is $734.5M.
